stockrow
Friday 6 November 2026
Export REPL’s income statement to Excel — free account
Replimune Group, Inc.
REPL Healthcare Biotechnology
- EPS
- +39.7%
- Free cash flow
- +42.2%
- Total debt
- +74.3%
Quarter to September 2026, against a year earlier
21.72
1.70
+8.49%
Follow REPL
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM Sep ’26 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 35 | 196 | 335 | +210.3% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (8) | (20) | (31) | (53) | (81) | (118) | (174) | (215) | (247) | (314) | (272) | +51.0% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (8) | (20) | (31) | (53) | (81) | (118) | (174) | (216) | (247) | (314) | (271) | +51.0% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (1.55) | (3.96) | (1.33) | (1.54) | (1.75) | (2.26) | (2.99) | (3.24) | (3.07) | (3.38) | (2.79) | +9.1% | ||||||
| Cash flow | (1.42) | (3.22) | (1.09) | (1.77) | (1.33) | (1.57) | (2.20) | (2.79) | (2.39) | (3.02) | (2.33) | +8.7% | ||||||
| Capex | (0.05) | (0.03) | (0.11) | (0.19) | (0.05) | (0.04) | (0.04) | (0.09) | (0.08) | (0.05) | 0.00 | (0.6%) | ||||||
| Free cash flow | (1.47) | (3.24) | (1.21) | (1.96) | (1.38) | (1.62) | (2.24) | (2.87) | (2.47) | (3.07) | (2.34) | +8.5% | ||||||
| Book value | (2.32) | (5.64) | 5.94 | 5.36 | 10.78 | 7.88 | 9.54 | 5.63 | 5.16 | 1.79 | 1.95 | n/m | ||||||
| Shares, m | 5 | 5 | 23 | 34 | 46 | 52 | 58 | 67 | 81 | 93 | 97 | +38.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (7) | (16) | (25) | (61) | (61) | (82) | (128) | (185) | (192) | (280) | (246) | +50.5% | |||||
| Capex | 0 | 0 | (3) | (7) | (2) | (2) | (2) | (6) | (7) | (4) | 0 | +37.7% | ||||||
| Free cash flow | (7) | (16) | (28) | (67) | (64) | (85) | (130) | (191) | (199) | (285) | (246) | +50.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 20 | 60 | 131 | 162 | 469 | 383 | 559 | 393 | 434 | 221 | 278 | +30.3% | |||||
| Net debt | (21) | (62) | (128) | (134) | (452) | (371) | (531) | (352) | (415) | (164) | (187) | +25.9% | ||||||
| Shareholders’ equity | (12) | (28) | 138 | 184 | 499 | 411 | 555 | 375 | 416 | 166 | 205 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (17.52) | (44.79) | (28.10) | (27.10) | (20.81) | (23.51) | (31.47) | (38.05) | (47.60) | (71.05) | (71.01) | (53.5) pt | |||||
| ROIC | 0.00 | 0.00 | (201.35) | (70.34) | (105.94) | (184.96) | (451.38) | (665.18) | (14,280.95) | (8,036.55) | (928.27) | (8,036.5) pt | ||||||
| ROE | 38.93 | 99.55 | (56.17) | (32.73) | (23.70) | (25.94) | (36.06) | (46.42) | (62.58) | (107.88) | (115.80) | (146.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | 44 | 67 | 122 | 152 | 206 | 284 | 331 | 479 | 465 | — | +34.3% | |||||
| Revenue/emp, $m | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 2 Nov 2026
Replimune Group, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings Inc. | $2.0B | — (loss-making) | — (loss-making) | −1.40% (below 0%: shrinking) | n/m | −33.96% (below 0%: shrinking) | 20.17% | 2.17% | Compare |
| TRAX First Tracks Biotherapeutics, Inc. | $1.9B | — (loss-making) | — | — | n/m | +55.91% (above 0%: growing) | — | 0.00% | Compare |
| REPL Replimune Group, Inc. | $1.9B | — (loss-making) | — | — | n/m | +42.22% (above 0%: growing) | 0.00% | 0.00% | |
| HRMY Harmony Biosciences Holdings, Inc. | $1.9B | 10.7× | 9.9× | +12.30% (above 0%: growing) | −6.24% (below 0%: shrinking) | −29.42% (below 0%: shrinking) | 70.00% | 20.15% | Compare |
| SRPT Sarepta Therapeutics, Inc. | $1.9B | — (loss-making) | 6.3× | −4.51% (below 0%: shrinking) | n/m | +231.84% (above 0%: growing) | 0.00% | (2.37%) | Compare |
| VIR Vir Biotechnology, Inc. | $1.9B | — (loss-making) | — (loss-making) | −178.33% (below 0%: shrinking) | n/m | +200.47% (above 0%: growing) | 100.00% | 55,669.15% | Compare |
| MESO Mesoblast Limited | $1.8B | — (loss-making) | — | −13.41% (below 0%: shrinking) | n/m | −89.23% (below 0%: shrinking) | (353.35%) | (909.40%) | Compare |
| TRVI Trevi Therapeutics, Inc. | $1.8B | — (loss-making) | — | — | n/m | −73.77% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MAZE Maze Therapeutics, Inc. | $1.8B | — (loss-making) | — | — | n/m | +50.21% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $1.9B | — | — | −4.51% | — | +10.39% | 20.17% | 0.00% |
Pay and ownership Proxy statement filed 29 July 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2026 | 5.85m | 3.62m | 43.32 |
| 2025 | 3.70m | 4.88m | 55.21 |
| 2024 | 6.02m | 1.15m | 46.26 |
Ownership
Directors and executive officers, together
5.40%
Entities affiliated with Baker Bros. Advisors LP
29.90%
RTW Investments, LP
8.80%
Ridgeback Capital Investments L.P.
7.50%
BlackRock, Inc
5.40%
Suvretta Capital Management, LLC
5.00%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement